Dream Unlimited Corp. Downgraded by Analyst, Estimates Cut for 2025

Dream Unlimited Corp.'s (TSE:DRM) analyst has downgraded forecasts for this year, cutting both revenue and EPS estimates. The new consensus is for revenues of CA$375m in 2025, a 12% decline from last year, and EPS of CA$0.15, a 92% drop. The analyst expects a 22% annualised revenue decline to the end of 2025, lagging the wider industry.

Dream Unlimited Corp. (TSE:DRM) has faced a significant downgrade from its analysts, with estimates for both revenue and earnings per share (EPS) reduced for the year 2025. The new consensus forecast projects revenues of CA$375 million, a 12% decline from the previous year, and EPS of CA$0.15, marking a 92% drop from last year's figures. The analyst expects a 22% annualized revenue decline by the end of 2025, which is notably slower than the wider industry's growth rate [1].

The analyst cited several factors contributing to the downgrade, including persistent challenges in the healthcare sector and broader macroeconomic pressures. The company's recent strategic decisions and operational shifts have not yet shown a significant positive impact on financial performance, leading to the revised estimates.

Dream Unlimited Corp. has been facing headwinds in its core operations, particularly in its Medical Products and Therapies segment. The company has been grappling with soft demand for certain products and operational inefficiencies, which have impacted its financial performance. The pause in shipments of the NOVUM LVP infusion pump, as seen with Baxter International, has also been a factor affecting revenue growth [2].

The downgrade underscores the need for the company to implement more aggressive cost-cutting measures and strategic initiatives to bolster its financial health. Investors are closely watching the company's ability to execute on its plans to improve operational efficiency and expand its market reach.

In light of these developments, Dream Unlimited Corp. will need to demonstrate a clear path to recovery and growth to regain investor confidence. The company's ability to navigate the challenging healthcare landscape and implement effective strategies will be critical to its future success.

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-baxter-q2-2025-misses-eps-forecast-stock-drops-93CH-4197182
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-baxter-q2-2025-misses-eps-forecast-stock-drops-93CH-4197182